Suggested remit: To appraise the clinical and cost effectiveness of setmelanotide within its marketing authorisation for treating obesity and hyperphagia caused by Bardet-Biedl Syndrome (BBS) or Alström syndrome (AS).
Status Awaiting development
Technology type Medicine
Decision Awaiting decision
Process STA 2018
ID number 3947

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
30 March 2022 The topic was discussed at the Topic Selection Oversight Panel (TSOP) in March 2022. The panel concluded that the topic was suitable for a Highly Specialised Technologies (HST) evaluation.
30 March 2022 Topic selection
15 December 2021 (14:00) Scoping workshop
03 November 2021 - 01 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 September 2021 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual